Amdocs (NYSE: DOX) reported earnings on July 31. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended June 30 (Q3), Amdocs met expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue grew. Non-GAAP earnings per share expanded significantly. GAAP earnings per share grew significantly.

Gross margins dropped, operating margins expanded, net margins grew.

Revenue details
 Amdocs logged revenue of $841.3 million. The 12 analysts polled by S&P Capital IQ predicted a top line of $841.8 million on the same basis. GAAP reported sales were 4.0% higher than the prior-year quarter's $808.8 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.

EPS details
 EPS came in at $0.83. The 14 earnings estimates compiled by S&P Capital IQ forecast $0.72 per share. Non-GAAP EPS of $0.83 for Q3 were 19% higher than the prior-year quarter's $0.70 per share. GAAP EPS of $0.73 for Q3 were 24% higher than the prior-year quarter's $0.59 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.

Margin details
 For the quarter, gross margin was 35.0%, 70 basis points worse than the prior-year quarter. Operating margin was 14.6%, 100 basis points better than the prior-year quarter. Net margin was 14.2%, 200 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $852.4 million. On the bottom line, the average EPS estimate is $0.71.

Next year's average estimate for revenue is $3.35 billion. The average EPS estimate is $2.92.

Investor sentiment
 The stock has a four-star rating (out of five) at Motley Fool CAPS, with 198 members out of 207 rating the stock outperform, and nine members rating it underperform. Among 61 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 58 give Amdocs a green thumbs-up, and three give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Amdocs is outperform, with an average price target of $38.45.

Is Amdocs playing the right part in the new technology revolution? Computers, mobile devices, and related services are creating huge amounts of valuable data, but only for companies that can crunch the numbers and make sense of it. Meet the leader in this field in "The Only Stock You Need To Profit From the NEW Technology Revolution." Click here for instant access to this free report.